期刊文献+

台州地区临床分离的革兰阴性菌对亚胺培南耐药率的变迁 被引量:7

Vicissitudes of Resistance to Imipenem in Gram-negative Bacilli
原文传递
导出
摘要 目的调查近年来革兰阴性杆菌对亚胺培南的耐药率变化。方法收集2004年1月-2008年1月从医院住院患者各种临床标本中分离的革兰阴性杆菌,使用VITEK-AMS全自动微生物分析仪进行菌种的鉴定和药敏试验,对结果进行回顾性调查。结果共分离出革兰阴性杆菌6983株,92个细菌种,肠杆菌科细菌2986株,占42.8%;非发酵菌3961株,占56.7%;分离率前5位的细菌分别是大肠埃希菌、铜绿假单胞菌、鲍氏不动杆菌、肺炎克雷伯菌和洋葱伯克霍尔德菌;肠杆菌科细菌对亚胺培南的耐药率<1.0%;嗜麦芽寡养单胞菌、洋葱伯克霍尔德菌、脑膜脓毒金黄杆菌、铜绿假单胞菌和鲍氏不动杆菌对亚胺培南的耐药率分别为98.4%、97.0%、98.2%、70.1%和47.5%。结论临床分离的革兰阴性杆菌以非发酵菌为主,亚胺培南对肠杆菌科细菌具有非常强的体外抗菌活性,对非发酵菌的体外抗菌活性较差,铜绿假单胞菌和鲍氏不动杆菌对亚胺培南的耐药率呈上升趋势。 OBJECTIVE To investigate the vicissitudes of resistance to imipenem in Gram-negative bacilli isolated from clinical specimens. METHODS Gram-negative bacilli were isolated from various clinical specimens in our hosptial from Jan 2004 to Jan 2008. The identification and antimicrobiol susceptiblity test was determined by VITEK-AMS full automated microbiology analyzer. RESULTS A total of 6983 strains of Gram-negative bacilli were isolated,including 92 species and 2986 isolates of Enterobacteriaceae and 3961 isolates of non-fermenters, accounted for 42.8% and 56.7%, respectively. The resistant rate of Enterobacteriaceae to imipenem was lower than 1.0%. The resistant rates of Stenotrophornonas maltophilia , Burkholderia cepacia , Chryseobacteriurn meningosepticum, Pseudornonas aeruginosaand Acinetobacter baurnannii to imipenem were 98. 4%, 97. 0%, 98.2 %, 70.1% and 47.5 %, respectively. CONCLUSIONS Non-fermenters are predominant pathogens. Imipenem has high antimicrobial activity to Enterobacteriaceae in invro, but not to non-fermenters. The resistant rates of P. aeruginosa and A. baumannii to imipenem are increasing gradually.
出处 《中华医院感染学杂志》 CAS CSCD 北大核心 2009年第12期1573-1575,共3页 Chinese Journal of Nosocomiology
关键词 亚胺培南 抗菌活性 革兰阴性杆菌 Imipenem Antimicrobial activity Gram-negative bacilli
  • 相关文献

参考文献4

二级参考文献20

  • 1郑专杰,王睿.嗜麦芽窄食单胞菌的耐药机制[J].国外医学(呼吸系统分册),2005,25(1):34-37. 被引量:29
  • 2熊旭东,严慧萍,谢芳,孟秋,赵辉,沈晓红.lCU革兰阴性菌对常用抗生素耐药的动态分析[J].抗感染药学,2005,2(1):27-28. 被引量:2
  • 3徐元宏,沈继录,杨伯侠,周强,王中新.铜绿假单胞菌对亚胺培南耐药机制的研究[J].中华微生物学和免疫学杂志,2005,25(5):427-427. 被引量:8
  • 4Bergogne-Berezin E. Guideline on antimicrobial chemotherapy for prevention and treatment of infections in the ICU. J Chemother, 2001,1: 134-149.
  • 5Goossens H. MYSTIC program: summary of European data from 1997 to 2000. Diagn Microbiol Infect Dis, 2001, 41: 183-189.
  • 6Leblebicioglu H, Gunaydin M, Esen S, et al. Surveillance of antimicrobial resistance in gram-negative isolates from ICU in Turkey:analysis of data from the last 5 years. J Chemother, 2002, 14:140-146.
  • 7Karlowsky JA, Kelly LJ, Thornsberry C , et al. Susceptibility to fluoroquinolones among commonly isolated Gram-negative bacilli in 2000:TRUST and TSN data for the United States. J Autimicrob Agents , 2002,19: 21-31.
  • 8National Committee for Clinical Laboratory Standards. 2002. Performance standards for antimicrobial susceptibility testing. Approved standard M100-S12. National Committee for Clinical Laboratory Standards,Wayne, Pa.2002,1.
  • 9Chanawong A. M' Zali FH, Heritage J, et al. Three cefotaximases,CTX-M-9, CTX-M-13, CTX-M-14, among Enterobacteriaceae in the People's Republic of China. Antimicrob Agents Chemother, 2002, 46:630-637.
  • 10Donald HM,Scaife W,Amyes SG,et al.Sequence analysis of ARI-1,a nvel OXA betalactam ase,responsible for imipenem resistance in Acientobacter baumannii 6B92[J].Antimicrob Agents Chemother,2000,44(1):196.

共引文献510

同被引文献50

引证文献7

二级引证文献38

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部